Eupraxia Pharmaceuticals (EPRX) Competitors $5.46 +0.08 (+1.39%) As of 07/3/2025 03:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. SION, IOVA, CDXC, GHRS, EOLS, XNCR, KALV, AUTL, SANA, and SAGEShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Sionna Therapeutics (SION), Iovance Biotherapeutics (IOVA), ChromaDex (CDXC), GH Research (GHRS), Evolus (EOLS), Xencor (XNCR), KalVista Pharmaceuticals (KALV), Autolus Therapeutics (AUTL), Sana Biotechnology (SANA), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Its Competitors Sionna Therapeutics Iovance Biotherapeutics ChromaDex GH Research Evolus Xencor KalVista Pharmaceuticals Autolus Therapeutics Sana Biotechnology Sage Therapeutics Sionna Therapeutics (NASDAQ:SION) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership. Which has stronger valuation and earnings, SION or EPRX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AEupraxia PharmaceuticalsN/AN/A-$25.50M-$0.76-7.19 Does the media prefer SION or EPRX? In the previous week, Sionna Therapeutics and Sionna Therapeutics both had 6 articles in the media. Sionna Therapeutics' average media sentiment score of 1.15 beat Eupraxia Pharmaceuticals' score of 0.79 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SION or EPRX more profitable? Sionna Therapeutics' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Eupraxia Pharmaceuticals N/A -367.73%-112.23% Do analysts rate SION or EPRX? Sionna Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 81.69%. Eupraxia Pharmaceuticals has a consensus target price of $11.00, indicating a potential upside of 101.28%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryEupraxia Pharmaceuticals beats Sionna Therapeutics on 5 of the 8 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$193.85M$2.91B$5.53B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-7.1921.5627.4020.24Price / SalesN/A274.65418.19125.29Price / CashN/A41.9536.6357.47Price / BookN/A7.518.085.67Net Income-$25.50M-$55.05M$3.16B$248.47M7 Day Performance3.11%4.59%2.81%3.29%1 Month Performance37.66%4.86%3.69%5.18%1 Year Performance118.60%5.82%35.30%21.35% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals2.4434 of 5 stars$5.47+1.4%$11.00+101.3%+118.6%$193.85MN/A-7.1929Gap UpSIONSionna TherapeuticsN/A$16.04+13.8%$38.50+140.0%N/A$622.15MN/A0.0035Positive NewsInsider TradeIOVAIovance Biotherapeutics4.7136 of 5 stars$1.88+1.6%$12.22+550.1%-76.3%$617.78M$164.07M-1.52500Trending NewsCDXCChromaDex3.2398 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120GHRSGH Research1.9356 of 5 stars$12.54+7.4%$32.00+155.2%+23.7%$607.69MN/A-15.8710EOLSEvolus3.6182 of 5 stars$9.62+2.6%$23.75+146.9%-15.7%$604.78M$266.27M-10.81170XNCRXencor4.0381 of 5 stars$8.27-1.7%$28.00+238.6%-54.8%$598.55M$110.49M-2.70280High Trading VolumeKALVKalVista Pharmaceuticals4.1958 of 5 stars$11.70-1.9%$24.83+112.3%+1.5%$593.11MN/A-3.15100Upcoming EarningsHigh Trading VolumeAUTLAutolus Therapeutics2.581 of 5 stars$2.27+2.7%$9.32+310.6%-32.1%$588.17M$10.12M-2.58330Positive NewsSANASana Biotechnology2.629 of 5 stars$2.97+14.2%$9.83+231.1%-38.8%$586.24MN/A-3.38380Analyst ForecastGap UpSAGESage Therapeutics3.2511 of 5 stars$9.22-0.9%$8.93-3.1%-13.4%$582.37M$41.24M-1.59690 Related Companies and Tools Related Companies Sionna Therapeutics Competitors Iovance Biotherapeutics Competitors ChromaDex Competitors GH Research Competitors Evolus Competitors Xencor Competitors KalVista Pharmaceuticals Competitors Autolus Therapeutics Competitors Sana Biotechnology Competitors Sage Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EPRX Stock Alerts